IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. (INAB) on June 13, 2024, covering events occurring on June 12 and June 13, 2024. The filing primarily reports the results of the Company's Annual Meeting of Stockholders and the release of updated clinical trial data.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and clinical updates rather than financial performance.
Material Changes and Events
- Annual Meeting Results: Held on June 12, 2024. All proposals submitted to stockholders were approved.
- Director Elections: Two nominees, William Ho and Alan S. Roemer, were elected to serve as directors until the 2027 annual meeting. Both received significant majority support with approximately 25.15 million votes "For" each.
- Auditor Ratification: Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received 32,456,857 votes "For" versus 40,741 "Against".
- Clinical Update: On June 13, 2024, the Company issued a press release regarding updated data from the Phase 1 trial of its candidate INB-100, presented at the European Hematology Association 2024 Hybrid Congress.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the standard incorporation of the press release regarding the INB-100 trial data.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for details on the Phase 1 trial data for INB-100.
- Confirm the tenure of the newly elected directors (William Ho and Alan S. Roemer) through the 2027 annual meeting.
- Review the definitive proxy statement filed on April 26, 2024, for detailed background on the proposals voted upon.